Articles by Henry N. Young, PhD

The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.

Physicians' Perceptions of Relevant Prescription Drug Costs: Do Costs to the Individual Patient or to the Population Matter Most?
ByWilliam H. Shrank, MD, MSHS,George J. Joseph, MS,Niteesh K. Choudhry, MD, PhD,Henry N. Young, PhD,Susan L. Ettner, PhD,Peter Glassman, MBBS, MSc,Steven M. Asch, MD, MPH,Richard L. Kravitz, MD, MSPH 
Do the Incentives in 3-Tier Pharmaceutical Benefit Plans Operate as Intended? Results From a Physician Leadership Survey
ByWilliam H. Shrank, MD, MSHS,Henry N. Young, PhD,Susan L. Ettner, PhD,Peter Glassman, MBBS, MSc,Steven M. Asch, MD, MPH,Richard L. Kravitz